A new era in phosphate binder therapy: what are the options?
Author(s): Salusky IB Affiliation(s): Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, California 90095-1697, USA. isalusky@mednet.ucla.edu Publication date & source: 2006-12, Kidney Int Suppl., (105):S10-5. Publication type: Review Dietary restriction of phosphorus and current dialysis prescription are unable to maintain phosphorus levels within the recommended range (2.7-5.5 mg/dl) in patients with advanced chronic kidney disease (CKD). Therefore, phosphate binders that limit the absorption of dietary phosphorus are commonly prescribed for this patient group. The first phosphate binders were introduced more than 30 years ago and included aluminum salts; however, although effective binders, the use of these agents was subsequently restricted because of concerns over aluminum accumulation in the central nervous system, bone, and hematopoietic cells. In subsequent years, calcium salts, namely calcium carbonate and calcium acetate, became the most widely us
